Effect of hormonal therapy on the otoconial changes caused by estrogen deficiency

Sci Rep. 2022 Dec 30;12(1):22596. doi: 10.1038/s41598-022-27240-5.

Abstract

Benign paroxysmal positional vertigo (BPPV) is associated with menopause and/or osteopenia. Morphological changes in the otoconial layer have been reported after ovariectomy (OVX). Moreover, hormone replacement therapy decreases BPPV risk. However, knowledge concerning the effect of hormonal therapy on the otoconial changes caused by estrogen deficiency is limited. We aimed to examine the effect of hormonal therapy on otoconial changes caused by estrogen deficiency. We hypothesized that hormonal therapy could reduce otoconial changes caused by OVX. Eight-week-old C57BL/6 mice were divided into four groups: sham operation with implantation of vehicle (sham + v), OVX with implantation of vehicle (OVX + v), OVX with implantation of estradiol (E2) (OVX + E2), and OVX with implantation of raloxifene (RAL) (OVX + RAL) groups. Otoconial layer volume was measured by micro-CT at 4 weeks after OVX or the sham operation. The otic bullae were removed; immunohistochemistry was performed for estrogen receptor alpha and 4-hydroxynonenal. Otoconial layer volume was significantly higher in the OVX + v than in the sham + v group. E2 and RAL significantly reduced these changes in the endometrial layer. The staining of estrogen receptor alpha and 4-hydroxynonenal were stronger in the OVX + v than in the sham + v group but equal in the sham + v, OVX + E2, and OVX + RAL groups. These results indicate that E2 and RAL are effective against morphological changes of the otoconial layer caused by estrogen deficiency via oxidative stress reduction.

MeSH terms

  • Animals
  • Estradiol / pharmacology
  • Estrogen Receptor alpha*
  • Estrogens
  • Female
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Ovariectomy
  • Raloxifene Hydrochloride*

Substances

  • 4-hydroxy-2-nonenal
  • Estradiol
  • Estrogen Receptor alpha
  • Estrogens
  • Raloxifene Hydrochloride